Table 2. Univariate and multivariate CoxPH analysis of clinical factors and miRNA-signature risk-score in the combined dataset from both the training and validation cohorts (n = 242).
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| MiRNA RS (High Risk vs. Low Risk) | 4.5 (2.04–9.90) | 1.9 × 10−4 | 4.0 (1.8–8.9) | 7.3 × 10−4 |
| T stage (T1&2 vs. T3&4) | 1.7 (0.86–3.3) | 0.13 | 1.5 (0.70–3.2) | 0.30 |
| N stage (N0&1 vs. N2&3) | 2.5 (1.2–5.0) | 8.0 × 10−3 | 2.7 (1.2–5.7) | 0.01 |
| Age | 1.0 (0.98–1.0) | 0.86 | 1.0 (0.98–1.0) | 0.93 |
| Gender (Female vs. Male) | 1.31 (0.60–2.9) | 0.50 | 1.3 (0.57–2.9) | 0.53 |
| Chemotherapy (− vs. +) | 0.97 (0.5–1.9) | 0.94 | 0.46 (0.21–1.0) | 0.05 |